Publications by authors named "Xiaolu Tao"
Article Synopsis
- HBM4003 is a new heavy chain-only antibody designed to work with anti-PD-1 antibody toripalimab, aiming to treat advanced solid tumors like melanoma while maintaining safety.* -
- In a phase I trial involving 40 patients, 90% experienced some treatment-related adverse events, but no severe complications (grade 4 or 5) were reported; the treatment showed varying efficacy based on prior PD-1 treatment.* -
- Results indicated an objective response rate of 33.3% for treatment-naïve melanoma patients, and baseline Treg/CD4+ ratio was identified as a potential predictor of treatment efficacy.*
Article Synopsis
- Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction, and new treatments like efgartigimod and rozanolixizumab have shown promise in reducing symptoms by lowering IgG levels.
- The study aimed to evaluate the effect and safety of a new monoclonal antibody called batoclimab in patients with generalized MG through a randomized clinical trial involving 132 adults across 27 centers in China.
- Results indicated that batoclimab significantly improved patient outcomes, with 58.2% of treated patients achieving sustained improvement in daily activities compared to 31.3% in the placebo group, making the drug a potentially effective treatment option for MG.
Background: A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1.
Objective: The objective of this study was to assess the combination's drug-drug interaction potential in vivo using a validated cocktail of eight cytochrome P450 (CYP) and transporter probes.
Methods: We conducted an open-label single-sequence study in healthy adults (n = 20) given single-dose caffeine (CYP1A2 substrate), metoprolol (CYP2D6), flurbiprofen (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), midazolam (CYP3A4), digoxin (P-glycoprotein), and pravastatin (organic anion-transporting polypeptide), alone or with steady-state twice-daily DCV/ASV/BCV 30/200/75 mg (with or without additional BCV 75 mg to adjust for higher exposure in hepatitis C virus infection).
Aim: This open-label study investigated the effect of belatacept on cytokine levels and on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam, as CYP probe substrates after oral administration of the Inje cocktail in healthy volunteers.
Methods: Twenty-two evaluable subjects received the Inje cocktail on Days 1, 4, 7 and 11 and belatacept infusion on Day 4.
Results: Since belatacept caused no major alterations to cytokine levels, there were no major effects on CYP-substrate pharmacokinetics, except for a slight (16-30%) increase in omeprazole exposure, which was probably due to omeprazole-mediated, time-dependent CYP inhibition.
Background: Cobicistat (COBI) is an alternative pharmacoenhancer to ritonavir. A fixed-dose combination (FDC) tablet containing atazanavir (ATV) and COBI has been developed for the treatment of HIV-1-infected patients.
Methods: This open-label, single-centre, single-dose, crossover study, randomized 64 healthy subjects to one of eight treatment sequences.
Objective: Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC.
View Article and Find Full Text PDFObjective: CXCL10 (also known as interferon-γ-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in the immunopathogenesis of rheumatoid arthritis (RA). We undertook this phase II study to evaluate the efficacy and safety of MDX-1100, a fully human, anti-CXCL10 (anti-IP-10) monoclonal antibody, in RA patients whose disease responded inadequately to methotrexate (MTX).
Methods: Patients with active RA receiving stable doses of MTX (10-25 mg weekly) were randomized to receive intravenous doses of 10 mg/kg MDX-1100 (n = 35) or placebo (n = 35) every other week.
A fast, sensitive, and selective method for the simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma, using rosiglitazone-d(4) and N-desmethyl rosiglitazone-d(4) as the respective internal standards, has been developed and validated. The analytes in human plasma (50 microL sample aliquot) were isolated through supported liquid/liquid extraction (SLE) and separated by isocratic HPLC over a 3-min period. The precursor and product ions were detected by ESI-MS-MS with multiple reaction monitoring (MRM) in a triple quadrupole mass spectrometer.
View Article and Find Full Text PDF